The relationship between Cyclophosphamide for the treatment of Prostate Cancer Skeletal Metastasis by Noori, Ramin & Hakimian, Morteza
 
Pharmacy Updates 2018 
The relationship between Cyclophosphamide for the treatment of 








a MSc in Genetics, Department of 
Biology, Ahar branch of Islamic Azad 
University, Ahar, Iran. 
 
Abstract Presenter: 
Ramin Noori, MSc in Genetics; 
Department of Biology, Ahar branch of 








Morteza Hakimian, MSc in Genetics; 
Department of Biology, Ahar branch of 











Introduction: Cyclophosphamide is used to treat cancers and autoimmune diseases. 
It is used to quickly control the disease. Because of its toxicity, it is replaced as soon 
as possible by less toxic drugs. Regular and frequent laboratory evaluations are 
required to monitor kidney function, avoid drug-induced bladder complications and 
screening for bone marrow toxicity. 
Methods and Results: The statistical population consisted of 75 blocked and 
paraffinized prostate cancer samples and 60 healthy tissue samples obtained from the 
Iranian Tissue Bank. RNA was extracted using TRIzol™ precipitation method. 
Specific sequences were then amplified for both groups by RT-PCR. Afterward, 
specific regions were cut by RFLP technique. 
Results: Based on the results, 65% of the patient samples showed significant 
relationships with CD82 gene expression (P = 0.01, OR = 0.94, Cl = 0.61-2.23). The 
gene expression also increased with age to a certain degree in the patient group (P = 
0.1, OR = 0.82, Cl = 0.60 – 1.98). 
Conclusion: The expression Cyclophosphamide for the treatment of Prostate Cancer 
Skeletal Metastasis compared to  the control group. This result could indicate that 
the gene can be used as a biomarker for the identification of people at the risk of 
prostate cancer. 
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